The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension

The Effects of Mercaptopurine on Pulmonary Vascular Resistance and BMPR2 Expression in Pulmonary Arterial Hypertension

Botros et al discuss their study on the effects of mercaptopurine on pulmonary vascular resistance and BMPR2 expression in pulmonary arterial hypertension (PAH). PAH is an incurable disease characterized by vascular obliteration and luminal narrowing. Current vasodilator therapies have no proven eff...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2020-07, Vol.202 (2), p.296-299
Hauptverfasser: Botros, Liza, Szulcek, Robert, Jansen, Samara Ma, Kurakula, Kondababu, Goumans, Marie-José Th, van Kuilenburg, André B P, Vonk Noordegraaf, Anton, de Man, Frances S, Aman, Jurjan, Bogaard, Harm Jan
Format: Artikel
Sprache:eng
Schlagworte:
Drug therapy
Lung diseases
Pulmonary arteries
Pulmonary hypertension
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Botros et al discuss their study on the effects of mercaptopurine on pulmonary vascular resistance and BMPR2 expression in pulmonary arterial hypertension (PAH). PAH is an incurable disease characterized by vascular obliteration and luminal narrowing. Current vasodilator therapies have no proven effect on the underlying molecular and cellular changes in the PAH lung, which include the emergence of apoptosis-resistant cell populations and proliferation of endothelial cells.
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.202003-0473LE